10-Year Update Confirms Long-Term Survival Benefits for Weekly Paclitaxel

Share this content:
For patients with TNBC, paclitaxel is more effective when administered on a weekly basis.
For patients with TNBC, paclitaxel is more effective when administered on a weekly basis.

SAN ANTONIO— Long-term survival rates are better for paclitaxel administered every week than every 3 weeks in patients with triple-negative breast cancer (TNBC), according to exploratory analyses conducted as part of a 10-year update of phase 3 clinical trial data presented at the 2014 San Antonio Breast Cancer Symposium.

“In the entire population, adjuvant weekly paclitaxel and every-3-week docetaxel were associated with significantly improved DFS and marginally improved overall survival compared with every-3-week paclitaxel when given sequentially following AC (doxorubicin-cyclophosphamide),” reported lead study author Joseph A. Sparano, MD, of the Montefiore Medical Center, Albert Einstein College of Medicine, in Bronx, NY.

“For triple-negative disease, the most effective taxane regimen was weekly paclitaxel—the 10 year DFS [disease-free survival] rate improved from 59% to 69%, and OS [overall survival] rate improved from 66% to 75%.”

“All patients received 4 cycles of AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2) every 3 weeks, followed by taxane therapy with either: (1) paclitaxel 175 mg/m2 every 3 weeks for 12 weeks (P3), (2) paclitaxel 80 mg/m2 weekly for 12 weeks (P1), (3) docetaxel 100 mg/m2 every 3 weeks four 12 weeks (D3), or (4) docetaxel 35 mg/m2 weekly for 12 weeks (D1),” he noted. “Patients with ER [estrogen receptor]-positive breast cancer also received endocrine therapy for at least 5 years, including either tamoxifen and/or an aromatase inhibitor.”

The team previously reported that at a median follow-up of 5.3 years, DFS had improved with both adjuvant P1 and D3, compared with P3,and that both obesity and black race were independently associated with poorer outcome in patients with ER-positive cancers.

Now, at 12.1 years follow-up, Dr. Sparano reported that there remains no significant difference in DFS by taxane (P = 0.322) or schedule (P = 0.88)—but there was a significant interaction between taxane and schedule for both DFS and OS (P < 0.001 and P = 0.007, respectively).”

 For hormone receptor–positive, HER-negative/unknown disease, extended adjuvant endocrine therapy “may be more relevant in this population at risk for late relapse,” he noted.

Among these patients, black race and obesity (BMI ≥ 30 kg/m2) were each independently associated with poorer OS, confirming earlier findings.

Reference

  1. Sparano JA, Zhao F, Martino S et al. S3-03. Presented at: San Antonio Breast Cancer Symposium 2014. Dec. 9-13, 2014; San Antonio, TX.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs